Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study

Clinical Pharmacology in Drug Development

Volumn 3, Issue 3, 2014, Pages 207-214

  Punwani, Naresh ^a   Yeleswaram, Swamy ^a   Chen, Xuejun ^a   Bowman, Jill ^a   Soloviev, Maxim ^a   Williams, William ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

Clinical pharmacology; JAK inhibitor; QT prolongation; Ruxolitinib

Indexed keywords

MOXIFLOXACIN; PLACEBO; RUXOLITINIB; ANTIINFECTIVE AGENT; JANUS KINASE INHIBITOR; PYRAZOLE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ACTION POTENTIAL; ADOLESCENT; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME FACTOR; YOUNG ADULT;

ACTION POTENTIALS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEALTHY VOLUNTEERS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; JANUS KINASE INHIBITORS; MALE; MIDDLE AGED; PYRAZOLES; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 84899876262     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.90     Document Type: Article

References (11)

1. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INC B018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115:3109-3117.
2. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011; 51:1644-1654.
3. Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010; 38:2023-2031.
4. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012; 52:809-818.
5. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004; 15:475-495.
6. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350:1013-1022.
7. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther. 2007; 81:108-113.
8. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14. 2005; Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed October 17, 2012.
9. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease 1920. Ann Noninvasive Electrocardiol. 2003; 8:343-351.
10. Committee for Medicinal Products for Human Use. Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04). London, UK: European Medicines Agency; 2006.
11. Chen X, Williams WV, Sandor V, Yeleswaram S. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013; 53:721-730.